Published in Nat Med on December 20, 2005
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
A logical model provides insights into T cell receptor signaling. PLoS Comput Biol (2007) 2.25
DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol (2006) 1.80
GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. Nucleic Acids Res (2011) 1.75
Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta. Carcinogenesis (2008) 1.62
Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal (2009) 1.59
Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc Natl Acad Sci U S A (2008) 1.54
Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol (2008) 1.48
Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J Cell Biol (2006) 1.37
Scaffold proteins confer diverse regulatory properties to protein kinase cascades. Proc Natl Acad Sci U S A (2007) 1.35
Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol (2009) 1.21
Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res (2009) 1.20
Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene (2011) 1.11
GAB2--a scaffolding protein in cancer. Mol Cancer Res (2012) 1.09
Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. Eur J Hum Genet (2011) 1.09
Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein. EMBO J (2008) 1.06
Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature. Am J Pathol (2009) 1.06
Gab family proteins are essential for postnatal maintenance of cardiac function via neuregulin-1/ErbB signaling. J Clin Invest (2007) 1.04
Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. J Biol Chem (2009) 1.04
Abnormal hematopoiesis in Gab2 mutant mice. Blood (2007) 1.04
Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget (2011) 1.03
ErbB-2 signals through Plexin-B1 to promote breast cancer metastasis. J Clin Invest (2012) 1.01
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A (2014) 0.99
GAB2 amplifications refine molecular classification of melanoma. Clin Cancer Res (2009) 0.97
Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion. Breast Cancer Res (2012) 0.93
A novel Stat3 binding motif in Gab2 mediates transformation of primary hematopoietic cells by the Stk/Ron receptor tyrosine kinase in response to Friend virus infection. Mol Cell Biol (2007) 0.92
Gab2 facilitates epithelial-to-mesenchymal transition via the MEK/ERK/MMP signaling in colorectal cancer. J Exp Clin Cancer Res (2016) 0.92
Hunk is required for HER2/neu-induced mammary tumorigenesis. J Clin Invest (2011) 0.91
Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing. Mol Biosyst (2008) 0.91
The signaling adaptor GAB1 regulates cell polarity by acting as a PAR protein scaffold. Mol Cell (2012) 0.91
GAB2 induces tumor angiogenesis in NRAS-driven melanoma. Oncogene (2012) 0.89
Epithelial protein-tyrosine phosphatase 1B contributes to the induction of mammary tumors by HER2/Neu but is not essential for tumor maintenance. Mol Cancer Res (2011) 0.89
Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancer. Biotechnol Prog (2008) 0.89
Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation. Mol Biol Cell (2010) 0.87
CrkII transgene induces atypical mammary gland development and tumorigenesis. Am J Pathol (2009) 0.87
Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor. PLoS One (2014) 0.87
c-Jun N-terminal Kinase 2 Regulates Multiple Receptor Tyrosine Kinase Pathways in Mouse Mammary Tumor Growth and Metastasis. Genes Cancer (2011) 0.86
Gab docking proteins in cardiovascular disease, cancer, and inflammation. Int J Inflam (2013) 0.85
Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis. BMC Cancer (2014) 0.84
Computational Model of Gab1/2-Dependent VEGFR2 Pathway to Akt Activation. PLoS One (2013) 0.84
The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα. Nature (2017) 0.84
G(i)α proteins exhibit functional differences in the activation of ERK1/2, Akt and mTORC1 by growth factors in normal and breast cancer cells. Cell Commun Signal (2014) 0.83
Gab2 phosphorylation by RSK inhibits Shp2 recruitment and cell motility. Mol Cell Biol (2013) 0.83
DeAnnCNV: a tool for online detection and annotation of copy number variations from whole-exome sequencing data. Nucleic Acids Res (2015) 0.82
Structure and function of Gab2 and its role in cancer (Review). Mol Med Rep (2015) 0.81
Src homology phosphotyrosyl phosphatase-2 expression is an independent negative prognostic factor in human breast cancer. Histopathology (2013) 0.81
Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood (2016) 0.80
Gab2 is a novel prognostic factor for colorectal cancer patients. Int J Clin Exp Pathol (2015) 0.80
Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids. Carcinogenesis (2013) 0.80
Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways. Breast Cancer Res (2014) 0.79
Gab adapter proteins as therapeutic targets for hematologic disease. Adv Hematol (2011) 0.78
Interleukin-3 (IL-3)-induced c-fos activation is modulated by Gab2-calcineurin interaction. J Biol Chem (2008) 0.77
Hematopoietic colony formation from human growth factor-dependent TF1 cells and human cord blood myeloid progenitor cells depends on SHP2 phosphatase function. Stem Cells Dev (2012) 0.77
A novel phosphatidic acid-protein-tyrosine phosphatase D2 axis is essential for ERBB2 signaling in mammary epithelial cells. J Biol Chem (2015) 0.77
Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression. Oncogene (2015) 0.76
Novel inhibitors of a Grb2 SH3C domain interaction identified by a virtual screen. Bioorg Med Chem (2012) 0.76
Protein tyrosine phosphatases: new markers and targets in oncology? Curr Oncol (2008) 0.76
Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics. Breast Care (Basel) (2008) 0.75
The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42. Nat Commun (2016) 0.75
Oncogenic Signaling Adaptor Proteins. J Genet Genomics (2015) 0.75
Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Nat Commun (2016) 0.75
Expression of HER2 in Breast Cancer Promotes a Massive Reorganization of Gene Activity and Suggests a Role for Epigenetic Regulation. J Data Mining Genomics Proteomics (2012) 0.75
CLImAT-HET: detecting subclonal copy number alterations and loss of heterozygosity in heterogeneous tumor samples from whole-genome sequencing data. BMC Med Genomics (2017) 0.75
Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation. Cell Rep (2017) 0.75
The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells. Leuk Res (2013) 0.75
New insights into signalling networks regulating breast cancer stem cells. Breast Cancer Res (2012) 0.75
SHP2 regulates proliferation and tumorigenicity of glioma stem cells. J Neurooncol (2017) 0.75
GAB2 Amplification in Squamous Cell Lung Cancer of Non-Smokers. J Korean Med Sci (2017) 0.75
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A (2004) 7.96
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet (2006) 7.16
The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci (2003) 6.24
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature (2003) 5.27
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Mathematical models of protein kinase signal transduction. Mol Cell (2002) 4.08
Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell (2008) 3.95
Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet (2006) 3.81
Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med (2006) 3.66
PTP1B regulates leptin signal transduction in vivo. Dev Cell (2002) 3.61
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med (2004) 3.55
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest (2002) 3.36
Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science (2002) 3.12
Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A (2010) 3.03
Requirement for CDK4 kinase function in breast cancer. Cancer Cell (2006) 2.92
Esthetics and smile characteristics from the layperson's perspective: a computer-based survey study. J Am Dent Assoc (2008) 2.89
Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell (2004) 2.82
The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev (2008) 2.74
PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem (2005) 2.68
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem (2005) 2.60
Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res (2003) 2.55
Tumor-initiating cells are rare in many human tumors. Cell Stem Cell (2010) 2.54
Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics (2006) 2.53
The "Gab" in signal transduction. Trends Cell Biol (2003) 2.52
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell (2005) 2.51
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol (2010) 2.49
Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat (2007) 2.49
Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell (2002) 2.42
B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity (2007) 2.28
Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J Biol Chem (2002) 2.17
Analysis of genomic and proteomic data using advanced literature mining. J Proteome Res (2003) 2.16
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol (2013) 2.15
Stops along the RAS pathway in human genetic disease. Nat Med (2006) 2.10
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol (2005) 2.09
Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem (2008) 2.08
Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res (2004) 2.05
Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2. Mol Cell Biol (2002) 2.03
Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res (2009) 1.98
The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev (2007) 1.97
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol (2003) 1.96
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst (2011) 1.94
FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity (2007) 1.90
Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes (2008) 1.88
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest (2011) 1.84
An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. Dev Cell (2006) 1.84
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol (2004) 1.83
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A (2004) 1.82
Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res (2005) 1.82
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res (2007) 1.82
Direct identification of PTEN phosphorylation sites. FEBS Lett (2002) 1.80
Distinct roles for neutrophils and dendritic cells in inflammation and autoimmunity in motheaten mice. Immunity (2013) 1.80
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood (2009) 1.79
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2005) 1.73
Metaplastic carcinoma of the breast with neuroglial differentiation. Breast (2005) 1.73
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat (2005) 1.73
Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res (2009) 1.72
Cancer genomics: technology, discovery, and translation. J Clin Oncol (2012) 1.70
Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A (2011) 1.68
Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B. Mol Cell Biol (2007) 1.66
Shp1 regulates T cell homeostasis by limiting IL-4 signals. J Exp Med (2013) 1.64
Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem (2003) 1.59
Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest (2014) 1.58
The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol Cell (2005) 1.58
Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu Rev Immunol (2007) 1.56
IgE-dependent activation of sphingosine kinases 1 and 2 and secretion of sphingosine 1-phosphate requires Fyn kinase and contributes to mast cell responses. J Biol Chem (2005) 1.55
Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer (2012) 1.49
Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function. Blood (2013) 1.49
SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem (2002) 1.48
Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro. Proc Natl Acad Sci U S A (2012) 1.48
PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. Blood (2014) 1.48
Thrombolysis in patients with marked clinical fluctuations in neurologic status due to cerebral ischemia. Arch Neurol (2008) 1.47
Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome. Neuron (2007) 1.47
Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol (2005) 1.41
A neural survival factor is a candidate oncogene in breast cancer. Proc Natl Acad Sci U S A (2003) 1.41
Regulation of protein tyrosine phosphatase 1B by sumoylation. Nat Cell Biol (2006) 1.40
Biologic, demographic, and social factors affecting triple negative breast cancer outcomes. Clin J Oncol Nurs (2015) 1.39
MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest (2011) 1.39
Lrp6-mediated canonical Wnt signaling is required for lip formation and fusion. Development (2009) 1.37
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood (2011) 1.36
Live-cell imaging of enzyme-substrate interaction reveals spatial regulation of PTP1B. Science (2007) 1.36
Cellular and molecular targets of estrogen in normal human breast tissue. Cancer Res (2002) 1.35
SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal (2009) 1.35